Search This Blog

Thursday, August 6, 2026

Regenxbio pivotal RGX202 Duchenne trial meets primary endpoint, enabling accelerated-approval paths

 

Regenxbio pivotal RGX202 Duchenne trial meets primary endpoint, enabling accelerated-approval paths for RGX202 and RGX121

  • On its Q2 2026 earnings call, Regenxbio said pro forma cash now exceeds $310 million, extending runway into Q4 2027.
  • Regenxbio received a $100 million AbbVie milestone payment and $108 million from a follow-on offering, boosting cash resources.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)